4.7.1. Insomnia
Kent and Medway PRGC Policy recommendation on Melatonin for Jet Lag - Click Here
Kent & Medway Guideline on the Use of Melatonin for the Management of Sleep Disorders in Children, Adolescents, and Adults - Click Here
For Position Statement on the Off label use of Chloral Hydrate in the Management of Intrusive Movement and Motor Disorders in Children and Young People and summary for use in insomnia & MHRA Drug Safety Update Click Here
For Controlled drugs/benzodiazepine prescribing patient treatment
agreement Click Here
MEDWAY ONLY: For Benzodiazepine prescribing guidance in Primary Care (Do NOT Use the ‘treatment agreement’ in appendix 5. Please use the K&M Treatment agreement Mar/Apr 22) Click Here
Daridorexant should be prescribed in line with this Kent and Medway guidance
Daridorexant Prescribing Guidance Click Here
NICE TA 922 : Daridorexant for treating long-term insomnia
Daridorexant is recommended for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months in line with the NHS Kent and Medway guidance. The length of treatment should be as short as possible. Treatment with Daridorexant should be assessed within 3 months of starting and should be stopped in people whose long-term insomnia has not responded adequately. If treatment is continued, assess whether it is still working at regular intervals. The initiating clinician is responsible for the 3 month assessment of efficacy.
Pack |
---|
30 tablet |
Pack |
---|
30 tablet |
Pack |
---|
30 tablet |
Pack |
---|
30 tablet |
Pack |
---|
30 tablet |
Pack |
---|
30 tablet |
Pack |
---|
150 ml |
60 ml |
Pack |
---|
30 tablet |
Pack |
---|
60 tablet |
Pack |
---|
30 tablet |
Pack |
---|
28 tablet |
500 tablet |
7 tablet |
Pack |
---|
250 tablet |
28 tablet |
7 tablet |
Pack |
---|
200 ml |
300 ml |
Daridorexant should be prescribed in line with this Kent and Medway guidance
Daridorexant Prescribing Guidance (4. Nervous system - guidance page) Click Here
NICE TA 922 : Daridorexant for treating long-term insomnia
Daridorexant is recommended for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months in line with the NHS Kent and Medway guidance. The length of treatment should be as short as possible. Treatment with Daridorexant should be assessed within 3 months of starting and should be stopped in people whose long-term insomnia has not responded adequately. If treatment is continued, assess whether it is still working at regular intervals. The initiating clinician is responsible for the 3 month assessment of efficacy.
Pack |
---|
30 tablet (3 x 10 tablets) |
Pack |
---|
30 tablet (3 x 10 tablets) |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only